Mounjaro Headaches: Treatment Comparisons | Cured
Cheapest Mounjaro Headaches Treatment - UK Price £124.99
Get expert Mounjaro headaches treatment at the cheapest UK price from £124.99 plus £20 off first order with code Weightlossnew.
Takes less than 2 minutes to complete 100% online
Treatment from £124.99
Check if you're eligible
Your BMI
26.8ⓘ Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.
Our Pricing
Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.
2.5mg
1 pen • 4 Weeks
£31.25 / Per Week
Your starting dose – designed to help your body adjust gently to treatment
5mg
1 pen • 4 Weeks
£39.75 / Per Week
First step up – builds on your progress as your body adapts to treatment
7.5mg
1 pen • 4 Weeks
£50.00 / Per Week
Mid-range dose – for continued progression and enhanced results
10mg
1 pen • 4 Weeks
£56.25 / Per Week
Higher strength dose – supports significant weight loss progress
12.5mg
1 pen • 4 Weeks
£62.50 / Per Week
Advanced dose – for patients requiring stronger therapeutic effect
15mg
1 pen • 4 Weeks
£66.75 / Per Week
Maximum dose – the highest available strength for optimal results
0.25mg
1 pen • 4 Weeks
£17.25 / Per Week
Your starting dose – eases your body into treatment with minimal side effects
0.5mg
1 pen • 4 Weeks
£19.75 / Per Week
First step up – continues building tolerance for long-term success
1mg
1 pen • 4 Weeks
£24.75 / Per Week
Mid-range dose – where most patients start seeing meaningful results
1.7mg
1 pen • 4 Weeks
£37.25 / Per Week
Higher strength – supports accelerated weight loss progress
2.4mg
1 pen • 4 Weeks
£44.75 / Per Week
Maximum dose – the highest available strength for optimal weight management
1.5mg
1 pen • 4 Weeks
£20.75 / Per Week
Your starting dose – eases your body into treatment with minimal side effects
4mg
1 pen • 4 Weeks
£27.50 / Per Week
First step up – continues building tolerance for long-term success
9mg
1 pen • 4 Weeks
£35.00 / Per Week
Mid-range dose – where most patients start seeing meaningful results
25mg
1 pen • 4 Weeks
£49.75 / Per Week
Maximum dose – the highest available strength for optimal weight management
Understanding Mounjaro Headaches: Treatment Comparisons
Published on: June 03, 2026
If you're researching mounjaro headaches treatment UK options, understanding how tirzepatide compares to other weight loss medications is essential. At Cured Pharmacy, our UK-registered clinical team has supported thousands of patients through their weight loss journey, including managing common side effects like headaches.
Why Mounjaro Headaches Treatment UK Matters
Headaches are reported in approximately 6-8% of patients taking Mounjaro (tirzepatide) in clinical trials, typically occurring during the initial dose escalation phase [1]. These headaches are generally mild to moderate in severity and tend to resolve within the first 4-8 weeks of treatment as your body adjusts to the medication.
Understanding the headache profile of Mounjaro compared to other weight loss treatments helps patients and prescribers make informed decisions. While headaches can occur with any GLP-1 receptor agonist, the frequency, intensity, and duration vary significantly between different medications [1][2].
At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that most headache-related concerns can be effectively managed with simple interventions, and rarely require treatment discontinuation when properly supported by your clinical team.
Mounjaro Headache Frequency Compared to Other Treatments
In the SURPASS-1 clinical trial, headaches occurred in 6.4% of patients receiving the 5mg dose, 7.1% on the 10mg dose, and 8.3% on the 15mg maintenance dose [1]. This compares favourably to some alternative weight loss medications where headache incidence can be considerably higher.
Wegovy (semaglutide) demonstrated headache rates of approximately 14% across the STEP trial programme, nearly double that of Mounjaro at equivalent treatment stages [2]. Saxenda (liraglutide), which requires daily rather than weekly injections, showed headache occurrence in 13.6% of patients during clinical studies [3].
Oral medications like Mysimba (naltrexone/bupropion combination) report even higher headache rates, with up to 18% of patients experiencing this side effect during the titration phase [4]. This reflects the different mechanism of action affecting central nervous system pathways more directly.
Understanding the Clinical Data
It's important to note that clinical trial data represents controlled study conditions, and real-world experience may vary. Most headaches associated with GLP-1 receptor agonists are tension-type headaches rather than migraines, and they typically respond well to standard over-the-counter pain relief when needed [1][2].
Why Headaches Occur with Mounjaro and Similar Medications
Tirzepatide works by activating both GIP and GLP-1 receptors, which slow gastric emptying and modulate appetite-regulating hormones [1]. This dual mechanism can temporarily affect fluid balance, blood sugar regulation, and eating patterns during the adjustment period, all of which may contribute to headache development.
Dehydration is a common underlying factor, as reduced food intake and changes in thirst perception can lead to inadequate fluid consumption. Additionally, the medication's effect on blood glucose levels, particularly in the first few weeks, may trigger headaches in some patients as their metabolism adjusts [5].
The once-weekly dosing schedule of Mounjaro means patients experience a gradual rise and fall in medication levels throughout the week, which differs from daily injectable options like Saxenda. Some patients find this pattern reduces side effect intensity compared to daily dosing fluctuations [3].
Individual Variation in Response
Not every patient will experience headaches, and those who do often find they diminish significantly after the first month of treatment. Your UK prescriber will assess your individual risk factors during your clinical consultation, including migraine history, current medications, and hydration status.
| Treatment | Headache Incidence | Dosing Frequency | Starting Price |
|---|---|---|---|
| Mounjaro (tirzepatide) | 6-8% in trials | Once weekly | From £124.99 |
| Wegovy (semaglutide) | ~14% in trials | Once weekly | From £69.00 |
| Saxenda (liraglutide) | ~14% in trials | Daily injection | From £68.00 |
| Mysimba | Up to 18% in trials | Twice daily tablets | From £125.95 |
| Orlistat | <3% in trials | Three times daily | From £32.00 |
Practical Strategies for Managing Mounjaro Headaches
Maintaining optimal hydration is the single most effective preventive measure. Aim for at least 2-2.5 litres of water daily, increasing this amount during hot weather or physical activity. Many patients find setting regular hydration reminders helpful during the initial treatment weeks.
Gradual dose escalation, as prescribed by your UK clinician, allows your body to adapt to tirzepatide's effects. Never increase your dose faster than recommended, even if you're tolerating the current dose well. The standard MHRA-approved titration schedule exists specifically to minimise side effects whilst building therapeutic efficacy [1].
If headaches do occur, paracetamol or ibuprofen can be used for symptomatic relief, provided you have no contraindications to these medications. Take pain relief at the first sign of headache rather than waiting for it to intensify. Ensure you've eaten adequately and maintain regular meal timing to support stable blood glucose levels [5].
When to Contact Your Prescriber
Seek medical advice if headaches are severe, persistent beyond 8 weeks, accompanied by visual disturbances, or significantly impact your daily functioning. Your prescriber may recommend temporarily pausing dose escalation or exploring alternative treatment options if headaches prove intolerable despite management strategies.
Comparing Headache Management Across Weight Loss Treatments
Different weight loss medications present distinct side effect profiles, and headache management strategies vary accordingly. With Mounjaro, the once-weekly administration and gradual dose titration typically result in fewer headache complaints compared to daily injectable alternatives [1][2].
Orlistat-based treatments like Xenical work through an entirely different mechanism, blocking fat absorption in the digestive system rather than affecting hormone pathways. Headaches are uncommon with orlistat, reported in fewer than 3% of patients, making it an alternative for those particularly sensitive to GLP-1 effects [6].
Mysimba's dual-action on opioid and dopamine pathways means headaches are managed differently, often requiring slower titration and occasionally necessitating additional supportive medications during the adjustment phase [4]. The choice between treatments depends on your complete medical profile, which your UK prescriber will evaluate during consultation.
Getting Started with Mounjaro at Cured Pharmacy
Cured Pharmacy offers Mounjaro Weight Loss Injections from £135.00, with transparent upfront pricing shown before your free clinical consultation. Our UK-registered prescribers conduct thorough assessments to determine if Mounjaro is suitable for you, considering your medical history, current medications, and any concerns about potential side effects.
Your consultation takes under 3 minutes to complete online, and our clinical team reviews every submission individually. If prescribed, your medication is dispensed from our GPhC-registered pharmacy (9012511) in 100% discreet packaging with next-day delivery options available across the UK.
We also offer alternative weight loss treatments including Wegovy, Saxenda, and oral options, allowing your prescriber to recommend the most appropriate medication based on your individual circumstances and side effect sensitivity. Every prescription medication requires clinical assessment by a UK prescriber before dispensing.
Scientific References
- Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
- Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
- Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595-605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
- Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
- Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155-161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
- NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
- NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
- NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.
Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.
Trusted by thousands
Real people, real results
Jane L.
"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."
Ann-Marie
"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."
Sacha W.
"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."
Kimberly G.
"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"
Jennifer
"Great really helps cure those nasty habits can't wait for my next mounjaro pen."
How it Works?
Select from our recommended UK-licensed medications.
1Choose your treatment

Select safe UK treatments. Quick answers.
2Answer quick questions

We will deliver direct to you as quickly as tomorrow.
3Get it delivered fast

Start Your Assessment For Weight Loss
Start your journey to better health today.
- Reviewed by UK-based prescribers
- Takes under 3 minutes
- Discreet Packaging
Start Your Journey To Better Health Today
Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.
Start My Assessment Log in to Your AccountFaq
Medically reviewed by
Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)
Reviewed on: June 03, 2026
Last updated on 13 August 2026.
Review History
Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.
Why this page was updated on 13 August 2026
Content checked and updated as part of our periodic review, to ensure accuracy and currentness.
Current version (13 August 2026)
Edited by: The Editorial Team
Medically reviewed by:
Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist
How we source info.
When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.